Targeting TLR2 for vaccine development.
Targeting TLR2 for vaccine development.
复制标题
DOI：
10.1155/2014/619410
复制
发表时间：
2014
影响因子：
4.1
通讯作者：
Leitão A
中科院分区：
文献类型：
--
作者：
Basto AP;Leitão A
通过刺激先天免疫受体来调节特异性免疫的现有知识可能会对许多动物疾病产生新的和更有效的免疫策略。toll样受体（TLR）2靶向制剂，如合成脂肽和与脂蛋白融合表达的抗原，已被证明具有内在的佐剂特性，并在不同动物物种中有效地诱导细胞和体液免疫机制。然而，关于引起的免疫反应的概况，出现了相互矛盾的数据。因此，靶向TLR2用于疫苗开发的益处仍然存在争议，需要更多的研究来合理探索其特性。在这里，我们回顾了TLR2和TLR2诱导的免疫反应的主要特征，重点介绍了已报道的兽医动物。
Novel and more effective immunization strategies against many animal diseases may profit from the current knowledge on the modulation of specific immunity through stimulation of innate immune receptors. Toll-like receptor (TLR)2-targeting formulations, such as synthetic lipopeptides and antigens expressed in fusion with lipoproteins, have been shown to have built-in adjuvant properties and to be effective at inducing cellular and humoral immune mechanisms in different animal species. However, contradictory data has arisen concerning the profile of the immune response elicited. The benefits of targeting TLR2 for vaccine development are thus still debatable and more studies are needed to rationally explore its characteristics. Here, we resume the main features of TLR2 and TLR2-induced immune responses, focusing on what has been reported for veterinary animals.